A carregar...
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
The discovery of epidermal growth-factor receptor (EGFR)-activating mutations and the introduction of oral EGFR tyrosine kinase inhibitors (EGFR-TKIs) have expanded the treatment options for patients with non-small cell lung cancer. The first two reversible EGFR-TKIs, erlotinib and gefitinib, are ap...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3594037/ https://ncbi.nlm.nih.gov/pubmed/23493883 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S23165 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|